The company expects to enroll approximately 60 to 70 patients with treatment-naive, unresectable pancreatic adenocarcinoma in this single-arm, open-label trial, which will be conducted at multiple investigator sites
Mesothelioma is a type of cancer arising from the cells, known as mesothelium, with the majority of cancers beginning in the chest cavity. The incidence of mesothelioma increases
The biopharmaceutical company will now apply for wider European approval through the mutual recognition procedure (MRP). In the treatment of sexual deviations in men, administration of a drug
If the endpoints in the study are met, ZymoGenetics plans to submit a biologics licensing application (BLA) for rhThrombin to the FDA in late 2006. The 400 patient
Results from the phase IV efficacy trial were presented at the XIV International Symposium on Atherosclerosis. The results demonstrated that adding the HDL-boosting therapy Niaspan to statin therapy
Under the contract HGS will manufacture and deliver 20,000 treatment courses of the compound, Abthrax, to the strategic national stockpile. The company will also complete the additional laboratory
Currently Nutra Pharma owns 38.1% of ReceptoPharm. The merger will provide Nutra Pharma with 100% of the outstanding ReceptoPharm stock and complete ownership of the ReceptoPharm intellectual property.
The phase II study will explore the safety of Varisolve in 50 patients who have a patent foramen ovale (PFO), a defect estimated to be present in approximately
The study, which has enrolled a total of 31 returning patients from a previous trial and 54 new patients, will examine IR103, a second generation immunotherapy, as a
These experiments showed that at the highest level of dosing required by the FDA in preclinical studies, levels of the active compound exceeded 50,000 times the EC50 for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.